Resources Repository
-
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Cost-Effectiveness Analysis | Priority Setting/Ethics | Chronic Disease/Risk | Health/Medicine | Global -
ReportPublication 2018Human Development Indices and Indicators: 2018 Statistical Update
This report from the United Nations Development Programme (UNDP) presents the latest reporting on key …
This report from the United Nations Development Programme (UNDP) presents the latest reporting on key human development indices and statistics. It provides a snapshot of current conditions and long-term trends and culminates with a comprehensive statistical annex of human development composite indices and indicators across several dimensions (e.g., health, education, poverty, and inequality). The publication emphasizes that while people are living longer and are more educated than ever before, this may not automatically translate to…
Evidence Synthesis | Health Outcomes | Social Determinants | Health Systems | Climate/Environment | Economics/Finance | Education/Labor | Health/Medicine | Science/Technology | Global -
ReportPublication 2019Human Development Report 2019: Beyond Income, Beyond Averages, Beyond Today
This 2019 Human Development Report, published annually by the United Nations Development Programme (UNDP), explores …
This 2019 Human Development Report, published annually by the United Nations Development Programme (UNDP), explores the contemporary nature of inequalities in human development. Additional resources include digital versions and translations of the Report and the overview in more than 10 languages, an interactive web version of the Report, a set of background papers and think pieces commissioned for the Report, interactive data visualizations and databases of human development indicators, full explanations of the sources and…
Evidence Synthesis | Health Outcomes | Social Determinants | Health Systems | Climate/Environment | Economics/Finance | Education/Labor | Health/Medicine | Science/Technology | Global -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Evidence Synthesis | Cost-Effectiveness Analysis | Mathematical Models | Infectious Diseases | Health/Medicine | Global -
ArticlePublication 2019Cost-Effectiveness of Latent TB Screening before Immigration to Low-Incidence Countries
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening …
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening for active infections, screening for latent TB infection before immigration is rare. The authors used discrete event simulation to evaluate the cost-effectiveness preimmigration latent TB infection screening for migrants to low-incidence countries. They calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Their analysis when combined with research on sustainability, acceptability, and program implementation can…
Dynamic Simulation | Cost-Effectiveness Analysis | Mathematical Models | Infectious Diseases | Government/Law | Health/Medicine | Global -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine | Global -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Evidence Synthesis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology | North America -
ArticlePublication 2018Resource Allocation in Decision Support Frameworks
Multi-criteria decision-making frameworks expand on typical decision analyses (cost-effectiveness and cost-benefit) by explicitly incorporating value …
Multi-criteria decision-making frameworks expand on typical decision analyses (cost-effectiveness and cost-benefit) by explicitly incorporating value tradeoffs from decision makers and summarizing the performance of investment options. This is done across all chosen dimensions of value, based on the weights provided by the decision makers, but comes at a cost. Currently there is no widely accepted method to suggest how to determine a budget constraint using multi-attribute models or to measure willingness to pay for incremental…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Priority Setting/Ethics | Health Systems | Health/Medicine | Global -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | Decision Analysis | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Health/Medicine | North America